Business ❯ Biotechnology ❯ Pharmaceuticals

Clinical Research

Regulatory Affairs Investment Opportunities Market Performance Eupraxia Pharmaceuticals Inhibrx Biosciences Cancer Therapies Market Response

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Topline data could support an expedited FDA filing as a second confirmatory Phase 3 trial continues.

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Nektar Therapeutics’ Rezpegaldesleukin Trial Success Sends Shares Up 150%